1.37
-0.055(-3.87%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.39 |
| Day High | 1.4 |
| Day Low | 1.36 |
| 52-Week High | 1.66 |
| 52-Week Low | 0.28 |
| Volume | 85,370 |
| Average Volume | 2.33M |
| Market Cap | 496.04M |
| PE | -7.18 |
| EPS | -0.19 |
| Moving Average 50 Days | 1.32 |
| Moving Average 200 Days | 0.9 |
| Change | -0.06 |
If you invested $1000 in Lexicon Pharmaceuticals, Inc. (LXRX) 10 years ago, it would be worth $108.15 as of November 11, 2025 at a share price of $1.42. Whereas If you bought $1000 worth of Lexicon Pharmaceuticals, Inc. (LXRX) shares 5 years ago, it would be worth $1,145.16 as of November 11, 2025 at a share price of $1.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
GlobeNewswire Inc.
1 hours ago
THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
GlobeNewswire Inc.
Nov 08, 2025 7:30 PM GMT
Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of lifeTHE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Na
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
Study results further differentiate sotagliflozin from SGLT inhibitors and cardiac myosin inhibitorsTHE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from three studies o